

BioPharma

Latest Updates

Here are this week's BioPharma updates - **May 26th, 2025.**

Funding

- [CellCentric](#) (Cambridge, United Kingdom) raised \$120M in Series C funding to advance inobrodib, an oral p300/CBP inhibitor, for the treatment of multiple myeloma.
- [Juvenescence](#) (Ramsey, Isle of Man) raised \$76M in Series B-1 funding to advance its AI-enabled therapeutics pipeline and deliver key clinical readouts for age-related diseases.
- [ReproNovo](#) (Lausanne, Switzerland) raised \$65M in Series A funding to advance its Phase 2 pipeline targeting infertility and adenomyosis in reproductive medicine and women's health.
- [FORE Biotherapeutics](#) (PA, USA) raised \$38M in Series D-2 funding to advance Phase 2 trials of plixorafenib, a BRAF inhibitor for CNS tumors and other BRAF-driven cancers.
- [PHASE Scientific](#) (Hong Kong) raised \$34M in Series A funding to advance urine-based diagnostic technology for early disease detection across cancers, women's health, and infectious diseases.
- [Emtora Biosciences](#) (TX, USA) received a \$3M Cancer Prevention & Research Institute of Texas grant to support its Phase 3 trial of eRapa for familial adenomatous polyposis.
- [MantaBio](#) (MA, USA) raised \$2.5M in seed funding to accelerate development of its automated platform for microbial contamination detection in biologics manufacturing.
- [Life Molecular Imaging](#) (Berlin, Germany) received a \$2.16M Alzheimer's Drug Discovery Foundation grant to advance development of [18F]F-DED PET imaging for investigating neuroinflammation in Alzheimer's disease.
- [RevolKa Ltd.](#) (Sendai, Japan) raised \$1.4M in Series A extension funding to advance AI-driven protein engineering for drug discovery in rare diseases.
- [Entos Pharmaceuticals](#) (Edmonton, Canada) received a \$1M CureDuchenne Ventures grant to develop a muscle-targeting gene therapy for Duchenne muscular dystrophy using its Fusogenix PLV delivery platform.
- [Senti Biosciences](#) (CA, USA) received a \$1M California Institute of Regenerative Medicine grant to advance clinical development of SENTI-202, a Logic Gated CAR-NK cell therapy for hematologic malignancies.

- [ME Therapeutics](#) (Vancouver, Canada) received \$140K in funding to advance development of its mRNA therapeutic program targeting myeloid cell biology for cancer and inflammatory disease.
- [Eascra Biotech](#) (MA, USA) received a \$100K MassVentures SBIR Targeted Technologies (START) grant to support development of its Janus Base Nanoparticles (JBNps), a non-lipid nanoparticle drug delivery platform.

Emerging

- [Massalia Therapeutics](#) (Marseille, France) raised an undisclosed amount in seed funding to advance an IND-ready first-in-class therapeutic targeting cancer and fibrosis.
- [Apreo Health](#) (CA, USA) emerged from stealth to pioneer a non-destructive implant, the BREATHE Airway Scaffold, to relieve lung pressure in severe emphysema patients without harming healthy tissue.
- [Mubadala Bio](#) (Abu Dhabi, United Arab Emirates) launched to boost the UAE's pharmaceutical manufacturing capacity and global presence in life sciences by producing a wide range of medicines and supporting national drug security and innovation.
- [Elvinix](#) (DE, USA) is currently operating in stealth to develop a functional cure for Type 1 Diabetes through innovative biotech solutions.
- [Apoha](#) (London, United Kingdom) is currently operating in stealth to develop Sensory Intelligence that seamlessly integrates machines into physical reality.
- [epiome.ai](#) (London, United Kingdom) is currently operating in stealth mode to develop advanced AI-driven precision diagnostics aimed at transforming the early detection and personalized treatment of neurological diseases.

Post IPO Equity

- [Gyre Therapeutics](#) (CA, USA) raised \$20M through an underwritten public offering to advance its Phase 2 clinical trial of F351 for MASH-associated liver fibrosis, support R&D, manufacturing, working capital, and general corporate purposes.
- [NanoVibronix](#) (NY, USA) raised \$10M through an underwritten public offering to redeem debt and support general corporate purposes.
- [Poolbeg Pharma](#) (London, United Kingdom) raised \$6M through an oversubscribed placing and direct subscription of new ordinary shares to advance its clinical trials, extend its financial runway into 2027, and support working capital.
- [CEL-SCI](#) (VA, USA) raised \$5M through an underwritten public offering to fund the continued development of Multikine, general corporate purposes, and working capital.
- [Mainz Biomed](#) (Mainz, Germany) raised \$4M through a follow-on offering to support its operations and ongoing cancer diagnostics programs

- [Protagenic Therapeutics Inc.](#) (NY, USA) raised \$3.1M through warrant exercises to fund working capital and advance peptide-based drug candidates for stress-related and central nervous system disorders.
- [Telomir Pharmaceuticals](#) (FL, USA) raised \$3M through a direct equity investment from The Bayshore Trust, its largest shareholder, to strengthen its balance sheet and fund Telomir-1's upcoming IND submission for a rare disease indication.
- [XORTX Therapeutics](#) (Calgary, Canada) raised \$3M through a private placement to advance its gout programs and support working capital and general corporate purposes.
- [AB Science](#) (Paris, France) raised ~\$2M through a private placement to finance ongoing activities, primarily clinical development of its AB8939 program.
- [PreveCeutical Medical Inc.](#) (Vancouver, Canada) raised \$748K through a non-brokered private placement to pay outstanding payables, operating expenses, and general working capital.
- [NorthX Biologics](#) (Matfors, Sweden) raised an undisclosed amount through a growth equity investment to accelerate expansion, enhance facilities, broaden service lines, and extend its U.S. commercial reach.
- [Outlook Therapeutics, Inc.](#) (NJ, USA) raised an undisclosed amount through an underwritten public offering of common stock and warrants to support working capital and general corporate purposes.

Post IPO Debt

- [Teva Pharmaceutical](#) Industries (Tel Aviv, Israel) raised \$2.3B through an upsized offering of senior notes to fund tender offers for existing debt, pay related fees and expenses, and for general debt repayment purposes.
- [Idorsia Pharmaceuticals Ltd](#) (Allschwil, Switzerland) raised ~\$165M through a new money facility backed by bondholders to extend its cash runway to mid-2026 and support ongoing operations amid convertible debt restructuring.
- [Cizzle Biotechnology Plc](#) (London, United Kingdom) raised \$190K through a convertible loan note subscribed by an existing investor to support the roll-out of its early cancer test in the UK and Europe and advance its growth strategy.

Mergers and Acquisitions

- [Sanofi](#) (Paris, France) to acquire [Vigil Neuroscience](#) (MA, USA) for up to \$670M, adding the oral TREM2 agonist VG-3927 for Alzheimer's disease to its neurology pipeline.
- [Regeneron Pharmaceuticals, Inc.](#) (NY, USA) has agreed to acquire [23andMe](#) (CA, USA) for \$256M to bolster its drug discovery capabilities using 23andMe's extensive genetic data. The acquisition supports Regeneron's goal of improving human health through genetics-based research while maintaining 23andMe's consumer genetics business.

- [Waters Corporation](#) (MA, USA) has acquired [Halo Labs](#) (OR, USA), a developer of specialized imaging technologies for particle analysis in cell, protein, and gene therapies, to expand Waters' capabilities in analytical and bioprocessing testing for large molecule therapies.
- [Altos Labs](#) (CA, USA) acquired [Dorian Therapeutics](#) (CA, USA), an anti-aging startup, to expand its portfolio of longevity-focused therapeutics.

Partnerships

- [Pfizer](#) (NY, USA) and [3SBio Inc.](#) (Shanghai, China) announced a ~\$6.05B exclusive global (ex-China) licensing agreement for SSGJ-707, a bispecific antibody for cancer.
- [Orionis Biosciences](#) (MA, USA) and [Genentech](#) (CA, USA) announced a ~\$2.1B multi-year collaboration for the discovery of small-molecule monovalent glues using Orionis's Allo-Glue™ platform.
- [VantAI](#) (NY, USA) and [Blueprint Medicines](#) (MA, USA) expanded their collaboration to include additional drug programs targeting previously undruggable diseases, with VantAI eligible for up to \$1.67 billion in milestone payments and royalties.
- [CRISPR Therapeutics](#) (MA, USA) and [Sirius Therapeutics](#) (CA, USA) announced a \$95M partnership to co-develop and co-commercialize SRSD107, a next-generation Factor XI siRNA therapy for thromboembolic disorders, with options for up to two additional siRNA programs.
- [Murdoch Children's Research Institute](#) (Melbourne, Australia) and [Retro Biosciences](#) (CA, USA) announced a \$35M research and commercial licensing agreement to advance MCRI's blood stem cell technology for developing new personalized therapies for blood disorders.
- [GENFIT](#) (Loos, France) received a \$28.8M milestone payment from [Ipsen](#) (France) after Iqirvo (elafibranor) secured pricing and reimbursement approval for PBC in Italy, under their licensing and collaboration agreement.
- [Lamassu Biotech](#) (NC, USA) and [The Ohio State University](#) (OH, USA) announced a research collaboration to advance RABI-767, a novel therapeutic for acute pancreatitis in dogs and humans.
- [Synoligo Biotechnologies](#) (NC, USA) and [Lumiphore](#) (CA, USA) announced a partnership to develop next-generation lanthanide-based oligonucleotide probes for diagnostic tests and life science research.
- [Porton Advanced](#) (NJ, USA) and [Hualong Biological](#) (China) announced a partnership for Porton Advanced to provide end-to-end CDMO services supporting the development and clinical advancement of Hualong's Multi-Activated T Cell (MATC) therapy for solid tumors.
- [Rani Therapeutics](#) (CA, USA) and [Chugai Pharmaceutical Co., Ltd.](#) (Tokyo, Japan) announced a research agreement to evaluate the RaniPill® oral delivery platform with two molecules for undisclosed targets.

- [Skye Bioscience Inc.](#) (CA, USA) and [Arecor Therapeutics](#) (Cambridge, United Kingdom) announced a formulation development collaboration to create a higher concentration version of nimacimab, Skye's CB1 inhibitor for obesity, using Arecor's Arestat™ technology.
- [Maipl Therapeutics](#) (NY, USA) and Endosure (MD, USA) announced a strategic partnership to accelerate clinical development of MA-4604, a first-in-class non-hormonal endometriosis therapy, by incorporating the ENDOSURE TEST—a rapid, non-invasive diagnostic—for improved patient identification and trial efficiency.
- [Mirai Bio](#) (MD, USA) and [Thermo Fisher Scientific](#) (MA, USA) announced a strategic partnership, including a direct investment, to accelerate the co-development and manufacturing of novel nucleic acid therapeutics, leveraging Mirai's machine intelligence-driven platform and Thermo Fisher's cGMP services and global manufacturing capabilities.
- [Tempus AI](#) (IL, USA) and [Verastem Oncology](#) (MA, USA) announced a collaboration to develop a companion diagnostic (CDx) test for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC), leveraging Tempus' xT CDx assay to support ongoing and future clinical trials.
- [Viz.ai](#) (CA, USA), [Sanofi](#) (Paris, France), and [Regeneron](#) (NY, USA) announced a multi-year partnership to deploy and assess an AI-powered workflow for improved detection and management of high-risk COPD patients.
- [Antengene](#) (Shanghai, China) and [MSD](#) (NJ, USA) announced a global clinical collaboration to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.
- [Evoform Biosciences](#) (CA, USA) and [Pharma 1 Drug Store LLC](#) (Dubai, United Arab Emirates) announced a license and supply agreement granting Pharma 1 exclusive Middle East rights to SOLOSEC®, with Evoform receiving upfront, regulatory, and sales-based milestone payments and supplying the product at cost-plus.
- [Neurogen Biomarking](#) (IL, USA) and [Aranscia](#) (TX, USA) announced a partnership to utilize Aranscia's lab and software solutions to support Neurogen's blood-based biomarker platform for early detection of mild cognitive impairment and Alzheimer's disease.
- [RamSoft](#) (Toronto, Canada) and [Therapixel](#) (Nice, France) announced a commercial partnership to integrate Therapixel's AI-powered MammoScreen® breast imaging software into RamSoft's PowerServer™ and OmegaAI® platforms, enhancing cancer detection and radiologist workflow within cloud-based imaging systems.
- [Kaida BioPharma](#) (FL, USA) and [Northway Biotech](#) (Vilnius, Lithuania) announced a manufacturing agreement for KAD101, a novel prolactin receptor antagonist, to advance process development and cGMP production for an upcoming Phase 1 trial in platinum-resistant ovarian cancer.

- [Aptar Digital Health](#) (NY, USA) and [AstraZeneca](#) (Cambridge, United Kingdom) announced a licensing agreement to develop and commercialize AI-driven algorithms for early detection of cardiovascular, renal, and metabolic conditions such as chronic kidney disease during eye examinations.
- [Twist Bioscience](#) (CA, USA) and [Element Biosciences](#) (CA, USA) announced an expanded collaboration to develop exclusive library preparation and target enrichment workflows for Element's AVITI systems and Trinity flowcells, streamlining NGS applications for research and clinical markets.
- [Roche](#) (Switzerland) and [Broad Clinical Labs](#) (MA, USA) announced a strategic collaboration to develop and pilot clinical and research applications using Roche's next-generation SBX sequencing technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their parents.

Initial Public Offering (IPO)

- [Hinge Health](#) (CA, USA) raised an undisclosed amount through an initial public offering (IPO) to satisfy tax obligations related to equity compensation and support corporate activities.

Registered Direct Offering (RDO)

- [Jaguar Health](#) (CA, USA) raised \$1.5M through a registered direct offering to support general corporate purposes, including growth capital, working capital, operating expenses, debt repayment, and capital expenditures.

Closures and Layoffs

- [Prime Medicine, Inc.](#) (MA, USA) has announced they will be laying off 25% of their employees
- [Schrödinger](#) (NY, USA) has announced they will be laying off 60 employees which is approximately 7% of their workforce.
- [Eikon Therapeutics](#) (CA, USA) has announced a second round of layoffs in 19 months due to financial challenges stemming from changes in external circumstances.